Penicillin Prophylaxis in Sickle Cell Disease (PROPS)

Summary

To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.

Conditions

• Anemia, Sickle Cell
• Hematologic Diseases
• Hemoglobinopathies
• Infection (S. Pneumoniae)
• Pneumonia

Interventions

DRUG

penicillin

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• David Becton · University of Arkansas

• Ann Bjornson · Gamble Institute of Medical Research

• George Buchanan · University of Texas

• Neil Grossman · Children's Hospital Medical Center, Cincinnati

• C. Holbrook · East Carolina University School of Medicine

• Rathyi Iyer · University of Mississippi Medical Center

• Karen Kalinyak · Children's Hospital Medical Center, Cincinnati

• Thomas Kinney · Duke University

• Helen Maurer · University of Illinois at Chicago

• Scott Miller · New York Health Science Center

• Charles Pegelow · University of Miami

• Sergio Piomelli · Columbia University

• Gregory Reaman · Children's Hospital National Medical Center

• Alan Schwartz · Washington University School of Medicine

• Elliott Vichinsky · Children's Hospital & Medical Center

• Winfred Wang · St. Jude Children's Research Hospital

• Doris Wethers · St. Luke's Roosevelt Institute of Health Science

• Gerald Woods · Children's Mercy Hospital Kansas City

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Eligibility

Max Age

5 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1983-08-31

Completion

1994-10-31